StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Piqray / Vijoice (alpelisib by Quarter

Piqray / Vijoice (alpelisib — PIK3CA-mutated breast cancer & PROS syndrome) ($M)

QuarterlyAnnual

Novartis Piqray / Vijoice (alpelisib: $122M in Q3 2026, up 35.6% from a year earlier.

Latest, Q3 2026
122
Period ended Sep 30, 2026
Change on a year earlier
+35.6%
90 in Q3 2025
History
29 quarters
Since Q2 2019
Sources
21
Documents cited below

Where the Q3 2026 figure comes from

“|| Piqray/Vijoice 4 | 122 | 90 | 36 | 37”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPiqray / Vijoice (alpelisib — PIK3CA-mutated breast cancer & PROS syndrome) ($M)Year on yearSource
Q3 2026Sep 30, 2026122+35.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026123+10.8%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202681-19.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202581-25.7%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202590-18.9%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025111-7.5%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025100-8.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024109-16.8%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024111-13.3%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024120-7.7%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024109-6.0%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023131+17.0%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023128+24.3%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023130+52.9%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023116+58.9%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022112+28.7%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up piqray / Vijoice (alpelisib

Cite this data

StockData. (2026). Novartis Piqray / Vijoice (alpelisib ($M), quarterly Q2 2019–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-piqray-vijoice

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.